Evidence map›Paper›PMID 33245719›Full record

ArticleOncotarget2020

Auto-antibodies against apolipoprotein A-1 block cancer cells proliferation and induce apoptosis.

Nathalie Satta, Rémy Weppe, Sabrina Pagano, Miguel Frias, Catherine Juillard, Nicolas Vuilleumier

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 60% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Nathalie SattaDivision of Laboratory Medicine, Department of Diagnostic, Geneva University Hospitals, Geneva, Switzerland.
Rémy WeppeDivision of Laboratory Medicine, Department of Diagnostic, Geneva University Hospitals, Geneva, Switzerland.
Sabrina PaganoDivision of Laboratory Medicine, Department of Diagnostic, Geneva University Hospitals, Geneva, Switzerland.
Miguel FriasDivision of Laboratory Medicine, Department of Diagnostic, Geneva University Hospitals, Geneva, Switzerland.
Catherine JuillardDivision of Laboratory Medicine, Department of Diagnostic, Geneva University Hospitals, Geneva, Switzerland.
Nicolas VuilleumierDivision of Laboratory Medicine, Department of Diagnostic, Geneva University Hospitals, Geneva, Switzerland.
University Hospital of Geneva · CHUniversity of Geneva · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Auto-antibodies against apoA-1 (anti-apoA-1 IgGs) have been identified as important actors of atherosclerosis development through pro-inflammatory and pro-atherogenic properties and to also induce apoptosis in tumoral neuronal and lymphocyte derived cell lines through unknown mechanisms. The purpose of this study was to explore the cellular pathways involved in tumoral cell survival modulated by anti-apoA-1 antibodies. We observed that anti-apoA-1 antibodies induce growth arrest (in G2/M phase) and cell apoptosis through caspase 3 activation, accompanied by a selective p53 phosphorylation on serine 15. RNA sequencing indicated that anti-apoA-1 IgGs affect the expression of more than 950 genes belonging to five major groups of genes and respectively involved in i) cell proliferation inhibition, ii) p53 stabilisation and regulation, iii) apoptosis regulation, iv) inflammation regulation, and v) oxidative stress. In conclusion, anti-apoA-1 antibodies seem to have a role in blocking tumoral cell proliferation and survival, by activating a major tumor suppressor protein and by modulating the inflammatory and oxidative stress response. Further investigations are needed to explore a possible anti-cancer therapeutic approach of these antibodies in very specific and circumscribed conditions.

Indexed as

anti-apoA-1 antibodiesapoptosecell proliferationoxidative stress

Identifiers

PMID33245719
PMCPMC7679029
OpenAlexW3106409961

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.